ALTERITY THERAPEUTICS

3,9400

20-мая-25 09:30:14

15 мин. задержка

Акции

-0,1132

-2,79%

Сегодняшний диапазон

3,9400 - 3,9400

ISIN

N/A

Источник

NASDAQ

Alterity Therapeutics Prominently Featured at the International MSA Congress

12 май 2025 07:35:00 Источник Nasdaq GlobeNewswire
Alterity Therapeutics Announces Multiple Oral and Poster Presentations to be Featured at the International MSA Congress

07 май 2025 08:16:45 Источник Nasdaq GlobeNewswire
Alterity Therapeutics Granted U.S. FDA Fast Track Designation for ATH434 to Treat Multiple System Atrophy

05 май 2025 07:35:00 Источник Nasdaq GlobeNewswire
Appendix 4C – Q3 FY25 Quarterly Cash Flow Report

30 апр 2025 07:35:00 Источник Nasdaq GlobeNewswire
Alterity Therapeutics Presents ATH434-201 Phase 2 Clinical Trial Results at European MSA Symposium

28 апр 2025 07:35:00 Источник Nasdaq GlobeNewswire
Alterity Therapeutics Presents Encouraging New Data from its ATH434 Phase 2 Trial in Multiple System Atrophy at the American Academy of Neurology Annual Meeting

10 апр 2025 07:35:00 Источник Nasdaq GlobeNewswire
Alterity Therapeutics to Deliver an Oral Presentation of the Positive ATH434 Phase 2 Trial Results at the American Academy of Neurology Annual Meeting

03 апр 2025 07:35:00 Источник Nasdaq GlobeNewswire
Alterity Therapeutics Completes Last Patient Visit in ATH434-202 Open-Label Phase 2 Trial in Multiple System Atrophy

27 мар 2025 07:25:00 Источник Nasdaq GlobeNewswire
Alterity Therapeutics Raises A$40.0 million in Placement

10 фев 2025 07:25:00 Источник Nasdaq GlobeNewswire
Alterity Therapeutics Announces Positive ATH434 Phase 2 Trial Results in Multiple System Atrophy Led By Robust Clinical Efficacy

30 янв 2025 07:35:00 Источник Nasdaq GlobeNewswire
Appendix 4C – Q2 FY25 Quarterly Cash Flow Report

24 янв 2025 07:35:00 Источник Nasdaq GlobeNewswire
Alterity Therapeutics Issues Shareholder Letter Highlighting Pipeline Advances and Key Upcoming Milestones

09 янв 2025 07:25:00 Источник Nasdaq GlobeNewswire
Alterity Therapeutics Completes Last Patient Visit in ATH434-201 Phase 2 Clinical Trial in Early-Stage Multiple System Atrophy

04 дек 2024 07:35:00 Источник Nasdaq GlobeNewswire
Alterity Therapeutics Appoints Abby Macnish Niven as Company Secretary

19 ноя 2024 07:25:00 Источник Nasdaq GlobeNewswire
Alterity Therapeutics Announces Presentation on Tracking the Progression of Multiple System Atrophy at International Symposium

12 ноя 2024 07:35:00 Источник Nasdaq GlobeNewswire
Alterity Therapeutics Announces New Publication Describing Novel Mechanism of Action for ATH434

06 ноя 2024 07:35:00 Источник Nasdaq GlobeNewswire
Appendix 4C – Q1 FY25 Quarterly Cash Flow Report

31 окт 2024 07:35:00 Источник Nasdaq GlobeNewswire
Alterity Therapeutics to Participate in a Fireside Chat at the 2024 Maxim Healthcare Virtual Summit on 17 October 2024

14 окт 2024 07:35:00 Источник Nasdaq GlobeNewswire
Alterity Therapeutics Announces Presentation of New Data Describing Neuroprotection of ATH434 at Neuroscience Meeting

11 окт 2024 07:35:00 Источник Nasdaq GlobeNewswire
Alterity Therapeutics Raises Profile with Multiple Data Presentations at the International Congress of Parkinson’s Disease and Movement Disorders®

02 окт 2024 07:35:00 Источник Nasdaq GlobeNewswire

<<
<
1
>

Принимаю NetDania's website uses cookies. By continuing browsing our website, you agree to our Правила в отношении Cookies, Политика конфиденциальности and Правила и условия.